Hidradenitis Suppurativa: Trends in Real-World Treatment Patterns in the United States

An OMNY Health™ Poster

Given the changing treatment landscape, it is important to understand current treatment patterns for hidradenitis suppurativa (HS)

On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.


  • Results provide insights into real-world treatment patterns for HS within a diverse set of US healthcare settings.
  • Adalimumab use has increased steadily since the Food and Drug Administration approval for the treatment of HS, while incision/drainage procedures and laser surgeries have both seen steady declines.
  • As new treatments are developed and introduced, further analyses would be helpful to understand uptake of therapies and prescription patterns among HS patients.


Check Out More Events & Webinars…


By continuing to use the site, you agree to the use of cookies. More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below, then you are consenting to this.